Loading
A phase 3 trial of Savolitinib and Sunitinib in renal cell carcinoma, run by AstraZeneca, active and no longer recruiting.
Savolitinib vs. Sunitinib in MET-driven PRCC. is a phase 3 interventional study registered as NCT03091192 by AstraZeneca, with 60 participants enrolled, started 2017-07-25 and due to reach its primary completion in 2019-08-18. Interventions recorded: Savolitinib and Sunitinib. Results have been posted on the registry.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
60 enrolled.
95% CI 2.8 to NA; Figures from the ClinicalTrials.gov results section (first posted 2020-07-10), not from a publication · 95% CI 4.1 to 6.9
Source| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Progression Free Survival (PFS) by Blinded Independent Central Review (BICR)primary | Savolitinib QD | 33 | 7 months | 0.71 (0.37 to 1.36) | 0.313 | link |
| Sunitinib QD | 27 | 5.6 months |
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares PRCC, Savolitinib, Papillary renal cell carcinoma, Sunitinib.
Shares Savolitinib, Hutchmed, AstraZeneca, Small-molecule kinase inhibitors and the tag pipeline.
Shares Savolitinib, AstraZeneca, Small-molecule kinase inhibitors and the tag pipeline.
Shares Papillary renal cell carcinoma, Renal cell carcinoma and the tag pipeline.
Shares Savolitinib, AstraZeneca, Small-molecule kinase inhibitors and the tag pipeline.
Shares Sunitinib, Anti-angiogenic therapy, Small-molecule kinase inhibitors and the tag pipeline.
Shares Anti-angiogenic therapy, Renal cell carcinoma, Small-molecule kinase inhibitors and the tag pipeline.
Shares Sunitinib, Renal cell carcinoma and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/